truenat mtb  (MolBio Diagnostics)

Journal: PLOS Global Public Health

Article Title: Evaluating the health impact, health-system costs and cost-effectiveness of using TrueNat on stool samples compared to usual care for the diagnosis of paediatric tuberculosis in primary care settings: A modelling analysis

doi: 10.1371/journal.pgph.0004016

Figure Lengend Snippet: PHC = primary health centre, TB = tuberculosis. Boxes shaded in grey show activities undertaken at hospital level. Unshaded boxes show activities undertaken at PHC. The box with red outline shows where the stool-based TrueNat for bacteriological testing using the SOS method will be introduced under the intervention.

Article Snippet: Since 2020, WHO has recommended using TrueNat MTB, MTB Plus and MTB-RIF Dx assays, hereinafter referred to as TrueNat, developed by Molbio Diagnostics (India), as initial diagnostic tests for tuberculosis in adults and children with signs and symptoms of pulmonary disease [ , ].

Techniques:

Journal: PLOS Global Public Health

Article Title: Decentralized TB diagnostic testing with Truenat MTB Plus and MTB-RIF Dx vs. hub-and-spoke GeneXpert MTB/RIF Ultra in Mozambique and Tanzania: a cost and cost-effectiveness analysis

doi: 10.1371/journal.pgph.0004724

Figure Lengend Snippet: Health system facility-based cost per participant tested for tuberculosis, comparing point-of-care Truenat MTB assays versus hub-and-spoke Xpert Ultra MTB assays (standard of care, SoC) testing in the TB-CAPT Core Trial. Each segment within each stacked bar corresponds to a distinct cost category, illustrating its proportionate contribution to the total health system expenses for diagnostic testing in each arm of the trial. Training costs were grouped under communication and monitoring & evaluation (CME), while other consumables included sample preparation kits, fuel, personnel protective equipment, and other medical consumables. All costs are reported in 2022 US dollars. For legibility, costs labels are presented for only those categories where the cost is higher than $2.

Article Snippet: Options for PoC TB testing include Xpert EDGE [ ] and the Molbio Truenat MTB Plus and MTB-RIF Dx assays (“Truenat MTB assays”; Molbio Diagnostics, Verna, Goa, India) [ ].

Techniques: Diagnostic Assay, Sample Prep

Journal: PLOS Global Public Health

Article Title: Decentralized TB diagnostic testing with Truenat MTB Plus and MTB-RIF Dx vs. hub-and-spoke GeneXpert MTB/RIF Ultra in Mozambique and Tanzania: a cost and cost-effectiveness analysis

doi: 10.1371/journal.pgph.0004724

Figure Lengend Snippet: Cost-effectiveness acceptability curves comparing the incremental facility-based diagnostic cost per incremental participant initiating treatment within seven days of enrolment, comparing point-of-care Truenat arm to the hub-and-spoke standard of care. Solid vertical lines represent alternative thresholds for evaluating cost-effectiveness.

Article Snippet: Options for PoC TB testing include Xpert EDGE [ ] and the Molbio Truenat MTB Plus and MTB-RIF Dx assays (“Truenat MTB assays”; Molbio Diagnostics, Verna, Goa, India) [ ].

Techniques: Diagnostic Assay

Journal: BMC Microbiology

Article Title: Direct detection from sputum for drug-resistant Mycobacterium tuberculosis using a CRISPR-Cas14a-based approach

doi: 10.1186/s12866-025-03899-4

Figure Lengend Snippet: Schematic illustration of the CRISPR-Cas14a MTB RIF/INH platform for gene mutations detection. This figure provides a visual representation of the mechanism by which the CRISPR - Cas14a MTB RIF/INH platform identifies gene mutations related to drug resistance

Article Snippet: The World Health Organization (WHO) Consolidated Guidelines on Tuberculosis (Module 3: Diagnosis - Rapid Diagnostics for Tuberculosis Detection) recommend three primary molecular methods for initial TB diagnosis with concurrent drug-resistance detection: (1) Xpert MTB/RIF and Xpert MTB/RIF Ultra assays (Cepheid, USA), (2) Truenat MTB, MTB Plus, and MTB-RIF Dx assays (Molbio Diagnostics, India), and (3) moderate complexity automated nucleic acid amplification tests (NAATs) [ ].

Techniques: CRISPR

Journal: BMC Microbiology

Article Title: Direct detection from sputum for drug-resistant Mycobacterium tuberculosis using a CRISPR-Cas14a-based approach

doi: 10.1186/s12866-025-03899-4

Figure Lengend Snippet: Design and evaluation of gRNAs for the CRISPR-Cas14a MTB RIF/INH platform to detect RIF- and INH-resistant mutations. ( A ) ssDNA substrates including wild-type (WT) and mutated versions were used. Fluorescence intensity was measured at 2-min intervals over a period of one hour. ( B ) After 60 min, the fluorescence intensities among different gRNAs were compared. Statistical significance of the differences was evaluated using the unpaired t-test ( n = 3 technical replicates; bars represent mean ± S.E.M, ** p < 0.01, *** p < 0.001, **** p < 0.0001)

Article Snippet: The World Health Organization (WHO) Consolidated Guidelines on Tuberculosis (Module 3: Diagnosis - Rapid Diagnostics for Tuberculosis Detection) recommend three primary molecular methods for initial TB diagnosis with concurrent drug-resistance detection: (1) Xpert MTB/RIF and Xpert MTB/RIF Ultra assays (Cepheid, USA), (2) Truenat MTB, MTB Plus, and MTB-RIF Dx assays (Molbio Diagnostics, India), and (3) moderate complexity automated nucleic acid amplification tests (NAATs) [ ].

Techniques: CRISPR, Fluorescence

Journal: BMC Microbiology

Article Title: Direct detection from sputum for drug-resistant Mycobacterium tuberculosis using a CRISPR-Cas14a-based approach

doi: 10.1186/s12866-025-03899-4

Figure Lengend Snippet: Evaluation of the LOD and specificity of the CRISPR-Cas14aMTB RIF/INH platform for detecting MTBC. ( A ) The fluorescence levels of the CRISPR-Cas14aMTB RIF/INH platform were measured across a dilution series of Mtb H37Rv genomic DNA. A heatmap was generated to display the signals of the platform for each individual gRNA. ( B ) Fluorescent signals were transformed into to a binary test result using a cut-off signal that was more than 6 standard deviations above the no template control. The LOD was determined by performing six replicate reactions at each dilution. ( C ) The specificity of each individual gRNA was determined using DNA from six common NTM strains, H37Rv strain DNA, and E. coli DH5α. Negative controls, where reactions were performed without DNA. For LOD determination, six technical replicates were executed, and for the specificity test, three technical replicates were performed. The bars in the graphs represent the mean values ± standard error of the mean (S.E.M), with statistical significance indicated as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

Article Snippet: The World Health Organization (WHO) Consolidated Guidelines on Tuberculosis (Module 3: Diagnosis - Rapid Diagnostics for Tuberculosis Detection) recommend three primary molecular methods for initial TB diagnosis with concurrent drug-resistance detection: (1) Xpert MTB/RIF and Xpert MTB/RIF Ultra assays (Cepheid, USA), (2) Truenat MTB, MTB Plus, and MTB-RIF Dx assays (Molbio Diagnostics, India), and (3) moderate complexity automated nucleic acid amplification tests (NAATs) [ ].

Techniques: CRISPR, Fluorescence, Generated, Transformation Assay, Control